Egetis Therapeutics: H1 2022 Recap and Outlook | Company Interview
Our biotech analyst Dan Akschuti interviewed Egetis Therapeutics’ CEO Nicklas Westerholm as well as board member & main shareholder Peder Walberg on the progress the company has gone through since its formation in 2020 and the exciting path ahead towards market approval in a currently untreatable rare disease affecting newborns. Interested in our equity sales and research offering? Learn more on our websites: https://paretosec.com/ 00:00 – 06:40 Recap 06:40 – 09:25 Other plans with lead drug Emcitate 0925 – 12:12 Next triggers, 2H 2022, 2023 and 2024 12:12 – 14:52 Capital requirements & funding Disclaimer: This material has been produced by Pareto Securities for general guidance and information purposes only and shall be seen as marketing material.
The information provided should not be considered professional advice and is under no circumstances intended to be used or considered as financial or investment advice, a recommendation or an offer to sell, or a solicitation of any offer to buy any securities or other form of financial asset. The information should not be considered investment research and is consequently not prepared in accordance with the regulation regarding investment analysis. Furthermore, the information is not indented to be regarded as legal, financial, commercial, tax or accounting advice. The information provided in the material is obtained from public sources which Pareto Securities considers reliable.
However, the information has not been independently verified, and Pareto makes no guarantee as to its accuracy or completeness. We have taken reasonable care to ensure that, to the best of our knowledge, material information contained herein is in accordance with the facts and contains no omissions likely to affect its understanding. Please note that we make no assurance that the underlying forward-looking statements are free from errors.
The material reflects Pareto Securities’ assessment at the time of production and may change without further notice. Pareto do not intend, and do not assume any obligation to update or correct the information included in the material. Pareto Securities AS is subject to supervision by the Financial Supervisory Authority of Norway, and member of the Norwegian Securities Dealers Association.
Pareto Securities AB is subject to the supervision by the Financial Supervisory Authority of Sweden..